Atea Pharmaceuticals, Inc. AVIR 深 滬
已收盤 02-06 16:00:00 美东时间
4.15
+0.130
+3.23%
華盛通- 最 高4.172
- 今 開4.05
- 成交量 32.38万股
- 最 低 3.91
- 昨 收 4.02
- 總市值 3.24亿
- 52周最高 4.3399
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 2.455
- 委 比 42.96%
- 總股本 7812.68万
- 歷史最高 94.174
- 量 比 0.41
- 振 幅 6.52%
- 歷史最低 2.455
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals announced that its CEO, Jean-Pierre Sommadossi, PhD, and other management team members will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be live webcast and available on the company's website for 90 days. Atea, a clinical-stage biopharmaceutical company, focuses on developing oral antiviral therapies for serious viral diseases, leveraging its nucleos(t)ide prodrug pla...
01-06 12:00
Atea Pharmaceuticals Completes Enrollment Of Over 880 Treatment-naïve Patients In C-BEYOND Phase 3 Trial Of Fixed-dose Combination Bemnifosbuvir And Ruzasvir Compared To Sofosbuvir And Velpatasvir Regime For Hepatitis C Virus; Results Are Expected Mid-year 2026
In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical trial sites in up to
2025-12-22 20:05
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals announced that its CEO and management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025. A live webcast will be available on the company's website, with an archive stored for 90 days. The event will focus on Atea's antiviral therapies and pipeline developments, which aim to address serious viral infections.
2025-11-19 12:00
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported on their global Phase 3 program for the treatment of HCV with bemnifosbuvir and ruzasvir, with patient enrollment on track and top-line results expected mid-2026. New data presented at The Liver Meeting® highlighted the regimen's dual mechanism of action, high antiviral potency, and resistance barrier. The company also announced a new development program for hepatitis E virus (HEV) to address unmet medical needs in i...
2025-11-12 21:05
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Atea Pharmaceuticals will host a conference call on November 12, 2025, at 4:30 p.m. ET to discuss Q3 2025 financial results and provide a business update. Participants can join via phone or webcast. The company focuses on developing oral antiviral therapies for serious viral infections.
2025-11-05 12:00
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
Atea Pharmaceuticals will host a virtual HCV key opinion leader (KOL) event on November 13, 2025, to discuss topics including current HCV patient populations, early diagnosis, public policy, HCV eradication in North America, and new therapies. The panel will feature experts Jordan Feld, Eric Lawitz, Anthony Martinez, and Nancy Reau. Atea will also discuss its global Phase 3 clinical program evaluating the bemnifosbuvir and ruzasvir regimen, with ...
2025-10-22 11:00
Atea Pharma To Present New Data Supporting Combination Regimen Of Bemnifosbuvir As Potential For HCV Infection Treatment At The Liver Meeting 2025, AASLD
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced
2025-10-07 20:06
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
<p>Atea Pharmaceuticals announced new data supporting the combination regimen of bemnifosbuvir and ruzasvir for hepatitis C treatment to be presented at The Liver Meeting 2025. Three abstracts from Phase 2 and 1 studies will cover multi-scale modeling, resistance analysis, and food effect. The company aims to showcase this regimen as a potential best-in-class treatment and discussed its Phase 3 global trials. The event will include presentations ...
2025-10-07 12:00
